ICU Medical, Inc. $ICUI Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. grew its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 56.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 290,292 shares of the medical instruments supplier’s stock after buying an additional 104,798 shares during the period. Federated Hermes Inc.’s holdings in ICU Medical were worth $34,823,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ICUI. Smartleaf Asset Management LLC increased its position in shares of ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after acquiring an additional 101 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of ICU Medical by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock valued at $325,000 after purchasing an additional 107 shares during the period. Thrivent Financial for Lutherans increased its holdings in shares of ICU Medical by 0.6% in the second quarter. Thrivent Financial for Lutherans now owns 18,098 shares of the medical instruments supplier’s stock valued at $2,392,000 after purchasing an additional 114 shares during the period. Maryland State Retirement & Pension System raised its stake in shares of ICU Medical by 1.8% in the second quarter. Maryland State Retirement & Pension System now owns 7,233 shares of the medical instruments supplier’s stock worth $956,000 after purchasing an additional 129 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $149.90 on Friday. The company has a market capitalization of $3.70 billion, a PE ratio of -483.53 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. The company’s fifty day moving average price is $148.42 and its 200 day moving average price is $133.46. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $169.59.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. During the same period in the prior year, the company posted $1.59 EPS. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on ICUI. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Monday, January 19th. Piper Sandler increased their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Finally, KeyCorp upped their price target on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

Insider Buying and Selling

In other news, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the transaction, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. This represents a 24.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president owned 5,456 shares in the company, valued at $776,607.04. This trade represents a 14.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.50% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.